Regulation of DNA duplication by the mTOR signaling pathway

References

• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484.
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103(2):253–262.
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022):905–909.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–976.
   PubMed Web of Science ®Google Scholar
• Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10(3):457–468.
   PubMed Web of Science ®Google Scholar
• Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019;21(1):63–71.
   PubMed Web of Science ®Google Scholar
• Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Bio. 2020;21(4):183–203.
   Web of Science ®Google Scholar
• Harwood FC, Geltink RIK, O’Hara BP, et al. ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Sci Adv. 2018;4(9):eaar3938.
   PubMed Web of Science ®Google Scholar
• Nguyen JT, Haidar FS, Fox AL, et al. mEAK-7 forms an alternative mTOR complex with DNA-PKcs in human cancer. Iscience. 2019;17:190-+.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596–603.
   PubMed Web of Science ®Google Scholar
• Soulard A, Hall MN. SnapShot: mTOR signaling. Cell. 2007;129(2):434.
   PubMed Web of Science ®Google Scholar
• Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr Opin Cell Biol. 2009;21(2):209–218.
   PubMed Web of Science ®Google Scholar
• Zoncu R, Bar-Peled L, Efeyan A, et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H+-ATPase. Science. 2011;334(6056):678–683.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Xing XW, Liu Y, et al. Comprehensive network analysis of different subtypes of molecular disorders in lung cancer. Oncologie. 2020;22(2):107–116.
   Web of Science ®Google Scholar
• Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126(5):955–968.
   PubMed Web of Science ®Google Scholar
• Li Y, Inoki K, Vacratsis P, et al. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J Biol Chem. 2003;278(16):13663–13671.
   PubMed Web of Science ®Google Scholar
• Zeng H, Lu B, Zamponi R, et al. mTORC1 signaling suppresses Wnt/beta-catenin signaling through DVL-dependent regulation of Wnt receptor FZD level. Proc Natl Acad Sci U S A. 2018;115(44):E10362–E10369.
   PubMed Web of Science ®Google Scholar
• Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 2007;130(3):440–455.
   PubMed Web of Science ®Google Scholar
• Astrinidis A, Senapedis W, Coleman TR, et al. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J Biol Chem. 2003;278(51):51372–51379.
   PubMed Web of Science ®Google Scholar
• Kim E, Goraksha-Hicks P, Li L, et al. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol. 2008;10(8):935–945.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22.
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6(9):729–734.
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335–348.
   PubMed Web of Science ®Google Scholar
• Biterge Sut B, Ikinci Keles A. Prognostic and predictive significance of eukaryotic elongation factor 1D (eEF1D) in breast cancer: a potential marker of response to endocrine therapy. Oncologie. 2020;22(3):147–154.
   Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell. 2004;5(6):519–523.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Howell JJ, Asara JM, et al. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013;339(6125):1323–1328.
   PubMed Web of Science ®Google Scholar
• Robitaille AM, Christen S, Shimobayashi M, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science. 2013;339(6125):1320–1323.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Hoxhaj G, Ricoult SJH, et al. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351(6274):728–733.
   PubMed Web of Science ®Google Scholar
• Bakan I, Laplante M. Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol. 2012;23(3):226–234.
   PubMed Web of Science ®Google Scholar
• Grasso D, Renna FJ, Vaccaro MI. Initial steps in mammalian autophagosome biogenesis. Front Cell Dev Biol. 2018;6. DOI:10.3389/fcell.2018.00146
   PubMed Web of Science ®Google Scholar
• Dossou AS, Basu A. The emerging roles of mTORC1 in macromanaging autophagy. Cancers (Basel). 2019;11(10):1422.
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–1508.
   PubMed Web of Science ®Google Scholar
• Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem. 2005;280(27):25485–25490.
   PubMed Web of Science ®Google Scholar
• Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005;280(28):26089–26093.
   PubMed Web of Science ®Google Scholar
• Pearce LR, Huang X, Boudeau J, et al. Identification of protor as a novel rictor-binding component of mTOR complex-2. Biochem J. 2007;405(3):513–522.
   PubMed Web of Science ®Google Scholar
• Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006;16(18):1865–1870.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6(11):1122–U1130.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098–1101.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296–1302.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J. 2008;416:375–385.
   PubMed Web of Science ®Google Scholar
• Nguyen JT, Ray C, Fox AL, et al. Mammalian EAK-7 activates alternative mTOR signaling to regulate cell proliferation and migration. Sci Adv. 2018;4(5):eaao5838.
   Web of Science ®Google Scholar
• Pilie PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.
   PubMed Web of Science ®Google Scholar
• Wang YL, Xu HN, Liu TR, et al. Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells. Jci Insight. 2018;3(3). DOI:10.1172/jci.insight.98096.
   Web of Science ®Google Scholar
• Diffley JFX. Quality control in the initiation of eukaryotic DNA replication. Philos T R Soc B. 2011;366(1584):3545–3553.
   PubMed Web of Science ®Google Scholar
• Aguilera A, Garcia-Muse T. Causes of genome instability. Annu Rev Genet. 2013;47:1–32.
   PubMed Web of Science ®Google Scholar
• Masai H, Matsumoto S, You ZY, et al. Eukaryotic Chromosome DNA Replication: where, When, and How?. Annual Review of Biochemistry. 2005;307(1):89–130.
   Google Scholar
• Petropoulos M, Champeris Tsaniras S, Taraviras S, et al. Replication Licensing Aberrations, Replication Stress, and Genomic Instability. Trends Biochem Sci. 2019;44(9):752–764.
   PubMed Web of Science ®Google Scholar
• Jones RM, Mortusewicz O, Afzal I, et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene. 2013;32(32):3744–3753.
   PubMed Web of Science ®Google Scholar
• Kotsantis P, Silva LM, Irmscher S, et al. Increased global transcription activity as a mechanism of replication stress in cancer. Nat Commun. 2016;7. DOI:10.1038/ncomms13087
   Web of Science ®Google Scholar
• Vaziri C, Saxena S, Jeon Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell. 2003;11(4):997–1008.
   PubMed Web of Science ®Google Scholar
• Melixetian M, Ballabeni A, Masiero L, et al. Loss of Geminin induces rereplication in the presence of functional p53. J Cell Biol. 2004;165(4):473–482.
   PubMed Web of Science ®Google Scholar
• Klotz-Noack K, McIntosh D, Schurch N, et al. Re-replication induced by geminin depletion occurs from G2 and is enhanced by checkpoint activation. J Cell Sci. 2012;125(10):2436–2445.
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35.
   PubMed Web of Science ®Google Scholar
• Wu X, Li S, Hu X, et al. mTOR signaling upregulates CDC6 via suppressing miR-3178 and promotes the loading of DNA replication helicase. Sci Rep. 2019;9(1):9805.
   PubMedGoogle Scholar
• Muller D, Shin S, Goullet De Rugy T, et al. eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. JCI Insight. 2019;4(21). DOI:10.1172/jci.insight.121951.
   Web of Science ®Google Scholar
• Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85.
   PubMed Web of Science ®Google Scholar
• Aye Y, Li M, Long MJ, et al. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene. 2015;34(16):2011–2021.
   PubMed Web of Science ®Google Scholar
• Mathews CK. Deoxyribonucleotides as genetic and metabolic regulators. Faseb J. 2014;28(9):3832–3840.
   PubMed Web of Science ®Google Scholar
• Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem. 2006;75:681–706.
   PubMed Web of Science ®Google Scholar
• Kolberg M, Strand KR, Graff P, et al. Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta. 2004;1699(1–2):1–34.
   PubMed Web of Science ®Google Scholar
• Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8(3):180–192.
   PubMed Web of Science ®Google Scholar
• Wellen KE, Thompson CB. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell. 2010;40(2):323–332.
   PubMed Web of Science ®Google Scholar
• Chabes A, Georgieva B, Domkin V, et al. Survival of DNA damage in yeast directly depends on increased dNTP levels allowed by relaxed feedback inhibition of ribonucleotide reductase. Cell. 2003;112(3):391–401.
   PubMed Web of Science ®Google Scholar
• Huang M, Zhou Z, Elledge SJ. The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor. Cell. 1998;94(5):595–605.
   PubMed Web of Science ®Google Scholar
• Zhao X, Rothstein R. The Dun1 checkpoint kinase phosphorylates and regulates the ribonucleotide reductase inhibitor Sml1. Proc Natl Acad Sci U S A. 2002;99(6):3746–3751.
   PubMed Web of Science ®Google Scholar
• Lee YD, Elledge SJ. Control of ribonucleotide reductase localization through an anchoring mechanism involving Wtm1. Genes Dev. 2006;20(3):334–344.
   PubMed Web of Science ®Google Scholar
• Lee YD, Wang J, Stubbe J, et al. Dif1 is a DNA-damage-regulated facilitator of nuclear import for ribonucleotide reductase. Mol Cell. 2008;32(1):70–80.
   PubMed Web of Science ®Google Scholar
• Prakash S, Prakash L. Translesion DNA synthesis in eukaryotes: a one- or two-polymerase affair. Genes Dev. 2002;16(15):1872–1883.
   PubMed Web of Science ®Google Scholar
• Yousefi B, Samadi N, Ahmadi Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. Adv Protein Chem Struct. 2014;22:24–29.
   Google Scholar
• D’Angiolella V, Donato V, Forrester FM, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149(5):1023–1034.
   PubMed Web of Science ®Google Scholar
• He Z, Hu X, Liu W, et al. P53 suppresses ribonucleotide reductase via inhibiting mTORC1. Oncotarget. 2017;8(25):41422–41431.
   PubMedGoogle Scholar
• Shen C, Lancaster CS, Shi B, et al. TOR signaling is a determinant of cell survival in response to DNA damage. Mol Cell Biol. 2007;27(20):7007–7017.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhou Y, Reske SN, et al. PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res. 2008;28(6A):3613–3619.
   PubMed Web of Science ®Google Scholar
• Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744–757.
   PubMed Web of Science ®Google Scholar
• Tamborero D, Gonzalez-Perez A, Perez-Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650.
   PubMed Web of Science ®Google Scholar
• Lamberti G, Brighi N, Maggio I, et al. The role of mTOR in neuroendocrine tumors: future cornerstone of a winning strategy? Int J Mol Sci. 2018;19(3):747.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease. Cell. 2017;170(4):605–635.
   PubMed Web of Science ®Google Scholar
• Oehlmann M, Score AJ, Blow JJ. The role of Cdc6 in ensuring complete genome licensing and S phase checkpoint activation. J Cell Biol. 2004;165(2):181–190.
   PubMed Web of Science ®Google Scholar
• Lau E, Zhu C, Abraham RT, et al. The functional role of Cdc6 in S-G2/M in mammalian cells. EMBO Rep. 2006;7(4):425–430.
   PubMed Web of Science ®Google Scholar
• Clay-Farrace L, Pelizon C, Santamaria D, et al. Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1. Embo J. 2003;22(3):704–712.
   PubMed Web of Science ®Google Scholar
• Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–323.
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421(6922):499–506.
   PubMed Web of Science ®Google Scholar
• Harrison JC, Haber JE. Surviving the breakup: the DNA damage checkpoint. Annu Rev Genet. 2006;40:209–235.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864–870.
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. Chromatin perturbations during the DNA damage response in higher eukaryotes. Adv Protein Chem Struct. 2015;36:8–12.
   Google Scholar
• Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Bio. 2013;14(4):197–210.
   Web of Science ®Google Scholar
• Wang X, Zou L, Lu T, et al. Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. Mol Cell. 2006;23(3):331–341.
   PubMed Web of Science ®Google Scholar
• Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 2003;300(5625):1542–1548.
   PubMed Web of Science ®Google Scholar
• Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28(5):739–745.
   PubMed Web of Science ®Google Scholar
• Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9(8):616–627.
   PubMed Web of Science ®Google Scholar
• Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18(10):622–636.
   PubMed Web of Science ®Google Scholar
• Sundar R, Brown J, Ingles Russo A, et al. Targeting ATR in cancer medicine. Curr Probl Cancer. 2017;41(4):302–315.
   PubMed Web of Science ®Google Scholar
• Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18(9):586–595.
   PubMed Web of Science ®Google Scholar
• Rundle S, Bradbury A, Drew Y, et al. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers (Basel). 2017;9(5):41.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu W, Hu X, et al. Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep. 2017;7(1):1535.
   PubMedGoogle Scholar
• Selvarajah J, Elia A, Carroll VA, et al. DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1. Oncotarget. 2015;6(1):427–440.
   PubMedGoogle Scholar
• Chinnam M, Goodrich DW. Rb1, development, and cancer. Curr Top Dev Biol. 2011;94:129–169.
   PubMed Web of Science ®Google Scholar
• Averous J, Fonseca BD, Proud CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene. 2008;27(8):1106–1113.
   PubMed Web of Science ®Google Scholar
• Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24(1):200–216.
   PubMed Web of Science ®Google Scholar
• Oka K, Ohya-Shimada W, Mizuno S, et al. Up-regulation of cyclin-E-1 via proline-mTOR pathway is responsible for HGF-mediated G(1)/S progression in the primary culture of rat hepatocytes. Biochem Biophys Res Commun. 2013;435(1):120–125.
   PubMed Web of Science ®Google Scholar
• Sumpter R, Levine B. Emerging functions of the Fanconi anemia pathway at a glance. J Cell Sci. 2017;130(16):2657–2662.
   PubMed Web of Science ®Google Scholar
• Niraj J, Farkkila A, D’Andrea AD. The fanconi anemia pathway in cancer. Annu Rev Canc Biol. 2019;3:457–478.
   PubMedGoogle Scholar
• Joo W, Xu GZ, Persky NS, et al. Structure of the FANCI-FANCD2 complex: insights into the fanconi anemia DNA repair pathway. Science. 2011;333(6040):312–316.
   PubMed Web of Science ®Google Scholar
• Knipscheer P, Raschle M, Smogorzewska A, et al. The fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science. 2009;326(5960):1698–1701.
   PubMed Web of Science ®Google Scholar
• Shen CX, Oswald D, Phelps D, et al. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res. 2013;73(11):3393–3401.
   PubMed Web of Science ®Google Scholar
• Guo F, Li J, Du W, et al. mTOR regulates DNA damage response through NF-kappaB-mediated FANCD2 pathway in hematopoietic cells. Leukemia. 2013;27(10):2040–2046.
   PubMed Web of Science ®Google Scholar
• Chaudhury I, Sareen A, Raghunandan M, et al. FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery. Nucleic Acids Res. 2013;41(13):6444–6459.
   PubMed Web of Science ®Google Scholar
• Lossaint G, Larroque M, Ribeyre C, et al. FANCD2 binds MCM proteins and controls replisome function upon activation of S phase checkpoint signaling. Mol Cell. 2013;51(5):678–690.
   PubMed Web of Science ®Google Scholar
• Michl J, Zimmer J, Buffa FM, et al. FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat Struct Mol Biol. 2016;23(8):755-+.
   PubMed Web of Science ®Google Scholar
• Dungrawala H, Rose KL, Bhat KP, et al. The replication checkpoint prevents two types of fork collapse without regulating replisome stability. Mol Cell. 2015;59(6):998–1010.
   PubMed Web of Science ®Google Scholar
• Shen CX, Bjornsti MA. TOR signaling maintains nucleolar architecture and timely exit from mitosis. Cancer Res. 2009;69(9).
   Web of Science ®Google Scholar
• Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2015;66:129–143.
   PubMed Web of Science ®Google Scholar